Leuppi‐Taegtmeyer AB, Reinau D, Yilmaz S, et al. - In smokers, researchers evaluated if enzyme‐inducing antiseizure drugs (ASDs) influence the risk of developing chronic obstructive pulmonary disease (COPD) or lung cancer in this population‐based case-control study. In the Clinical Practice Research Datalink UK database of patients managed in primary care (1995–2016), smokers with ≥1 prescription for any type of ASD were identified, and from this group, COPD and lung cancer cases along with matched controls with none of these conditions were included. They analyzed exposure to enzyme‐inducing ASDs relative to non–enzyme‐inducing ASDs in this matched case-control study using multivariate logistic regression. Five thousand nine hundred fifty-two incident COPD and 1,373 incident lung cancer cases, and 59,328 and 13,681 matched controls, respectively, were included. Slightly reduced risk estimates of COPD and lung cancer were seen with ever-use of enzyme‐inducing ASDs vs never-use. Such risk estimates were reduced in heavy smokers. Among smokers taking enzyme‐inducing ASDs slightly lower risk estimates of COPD and lung cancer were seen; this could be due to the induction of detoxification of tobacco‐specific lung toxins. .